Diabetes work gives new hope for 'cure'
A century ago, type 1 diabetes was a death sentence. But San Diego biotech ViaCyte says two studies published last week show the company is getting closer to what it calls a "funct…
A century ago, type 1 diabetes was a death sentence. But San Diego biotech ViaCyte says two studies published last week show the company is getting closer to what it calls a "funct…